Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
Cart
Search
nav search
Search
Toggle MenuMenu
Skip Nav Destination

Written in Blood

Research from recent issues of Blood
Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL
Does MRD Predict PFS in Patients With CLL on Indefinite Ibrutinib-Based Therapy?
Researchers Develop Optimized Inflammatory Index for Malignancy-Associated HLH Diagnosis and Mortality Prediction
Adding All-Trans Retinoic Acid to Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP
Liso-Cel Shows Promising Safety and Efficacy in Relapsed/Refractory CLL/SLL
Comparing AHCT Versus CAR T-Cell Therapy in Relapsed DLBCL
How Long Is the Indolent Preclinical Phase of High-Risk CLL?
POD24 Predicts Poor Prognosis in Follicular Lymphoma
Identifying Nosology of Splenic Marginal Zone B-Cell Lymphoma to Improve Targetable Therapy Development
BIOIRON Society Recommends New Classification of Hemochromatosis
No Difference in CNS Relapse Rates Between IT and IV Prophylaxis Routes in Non-Hodgkin Lymphomas
How Safe Is Vaccination Against SARS-CoV-2 for Patients With De Novo and Preexisting ITP?
Evaluating Pembrolizumab in Relapsed/Refractory B-Cell Lymphomas
Characterizing Long-Term Outcomes of Eltrombopag in Patients With Severe Aplastic Anemia
Routine Screening for Germline Variants in Patients With AML
Asciminib Superior to Bosutinib in Chronic-Phase CML
Show more items from this collection

Advertisement

  CURRENT ISSUE
  Mid-January 2022

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright ©2022 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement

X